Biomedical Occupation or Discipline
Senator Cassidy’s Crucial Vote Advances RFK Jr.’s HHS Secretary Nomination
Robert F. Kennedy Jr., Bill Cassidy, HHS Secretary nomination, Senate Finance Committee, vaccine safety, public health, Trump administration
Omega Therapeutics Faces Bankruptcy and Layoffs Despite Recent Novo Nordisk Obesity Deal
Omega Therapeutics, bankruptcy, layoffs, Novo Nordisk, obesity deal, Flagship Pioneering, epigenomics, financial struggles
Thermo Fisher Scientific Continues Workforce Reduction with 300 Layoffs in Massachusetts
Thermo Fisher Scientific, layoffs, Massachusetts, viral vector production, workforce reduction, biotechnology industry, cost-cutting measures
Inhibikase Halts Parkinson’s Drug Development After Phase II Failure, Shifts Focus to Pulmonary Arterial Hypertension
Inhibikase Therapeutics, risvodetinib, Parkinson’s disease, Phase II trial, clinical failure, drug development, pulmonary arterial hypertension (PAH), IkT-001Pro
Sage Therapeutics Rejects Biogen’s Acquisition Proposal, Remains Open to Future Deals
Sage Therapeutics, Biogen, Acquisition Proposal, Postpartum Depression, ZURZUVAE, Neurodevelopmental Disorders, Neuropsychiatry
Allakos Discontinues AK006 Development, Cuts 75% of Workforce Amid Strategic Restructuring
Allakos, AK006, workforce reduction, strategic alternatives, Phase 1 trial failure, chronic spontaneous urticaria (CSU), biotechnology, restructuring costs.
Breaking the Silence: Endo’s “I Got Somebody” Campaign Encourages Men to Seek Help for Peyronie’s Disease
Peyronie’s disease, men’s health, Endo, “I Got Somebody” campaign, urology specialists, nonsurgical treatment options, disease awareness, stigma reduction.
Vigil’s TREM2-Targeted Alzheimer’s Treatment Advances to Phase II with Promising Early Results
TREM2, Alzheimer’s disease, Vigil Neuroscience, VG-3927, Phase II clinical trial, microglial-targeted therapeutics
Retro Biosciences, Backed by Sam Altman, Seeks $1 Billion to Extend Human Lifespan by 10 Years
Retro Biosciences, Sam Altman, Human Lifespan Extension, Biotechnology, Series A Funding, Artificial Intelligence in Healthcare
Neomorph Secures $1.6 Billion Deal with AbbVie to Develop Molecular Glue Degraders for Oncology and Immunology
Neomorph, AbbVie, molecular glue degraders, oncology, immunology, protein degradation, drug development, biotechnology, pharmaceutical partnership.